Mirati Therapeutics falls on report of potential acquisition

Mirati Therapeutics

06/10/2023 10:09

** Shares of cancer drugmaker Mirati Therapeutics  MRTX.O 
fall 3% to $60.49 premarket
    ** Sanofi  SASY.PA  is exploring a potential acquisition of
MRTX, Bloomberg reported on Thursday
    ** Deliberations are ongoing and there is no certainty they
will result in an agreement - report
    ** A Sanofi spokesperson told Reuters the company does not
comment on market rumors, while Mirati also said it does not
comment on speculation
    ** YTD, MRTX up 37.7% as of last close

 (Reporting by Siddarth S in Bengaluru)
 ((Siddarth.s@thomsonreuters.com;))